1. Researchers found that adding metastasis-directed radiation therapy (MDT) to chemotherapy significantly improves progression-free survival for oligometastatic pancreatic cancer patients.
Researchers from The University of Texas MD Anderson Cancer Center have shown that adding metastasis-directed radiation therapy (MDT) to standard-of-care chemotherapy significantly improves progression-free survival (PFS) for patients with oligometastatic pancreatic cancer. The multicenter EXTEND trial found PFS was 10.3 months in patients who received MDT plus chemotherapy compared to 2.5 months in those who received standard chemotherapy treatment. MDT is a safe and effective treatment option, prompting a Phase III EXPAND trial to further investigate its benefits.
August 05, 2024
3 Articles